Abstract
Background: Non-Hodgkin lymphomas (NHLs) are heterogeneous group of lymphoproliferative malignancies with different patterns of behavior and response to treatment that usually originate in lymphoid tissues and can spread to other organs. The aim of the work was to evaluate transforming growth factor beta-1 (TGF-β1) in diffuse large cell B-cell lymphoma and response to R-CHOP protocol of therapy. Methods: This study had been conducted on 50 patients with diffuse large B-cell lymphoma, their ages ranged from 18 to 60 years with a mean age of 44.5 ± 10.7 years. Ten age- and sex-matched apparently healthy individuals were included as control group and the diagnosis and staging of diffuse large B-cell lymphoma was based on clinical, radiological and histopathological criteria. Results: Our study revealed that soluble TGF-β1 was significantly elevated in comparison to control group (P < 0.001), and it was correlated with advanced stages, bulky disease, high risk international prognostic index, and partially or non-responded patients (r = 0.6, 0.8, 0.3, and 0.2, respectively), TGF-β1 which was high in all patients. It was an independent risk factor for disease-free survival (DFS) (P = 0.007, hazard ratio (HR): 3.5) and overall survival (OS) (P = 0.003, HR: 5.8), along with poor performance status (PS); patients with high TGF-β1 initially showed inferior survival curves in non-responded compared with responded patients for treatment in OS (2-year OS of 72%, P < 0.001) and DFS (2-year DFS of 54%, P < 0.00). Conclusion: A significant relation was detected between TGF-β1 and treatment response as well as survival indicating its promising value as a prognostic and predictive marker for treatment outcome and survival. J Hematol. 2015;4(1):131-136 doi: http://dx.doi.org/10.14740/jh194w
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
